Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462456 · ClinicalTrials.gov registry record
Post-market Clinical Follow-up Study of Alcon PRECISION1™ Spherical and PRECISION1™ for Astigmatism Soft Contact Lenses
A clinical trial, sponsored by Alcon Research.
- Terminated
- Registry status
- 140
- Enrollment target
NCT06462456: Clinical Trial study, sponsored by Alcon Research.
NCT06462456 is a clinical trial that was terminated before completion, run by Alcon Research. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06462456 was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- 140 participants
- Enrollment target
Study Summary
The purpose of this study is to assess long term performance and safety of verofilcon A soft contact lenses in a real-world setting in a population of 7 years or older having at least 1 year of verofilcon A (sphere or toric) contact lens wear in a daily wear and daily disposable modality.
Primary Outcome
Visual acuity (VA) assessed per the investigator's standard of care with study lenses in place.
Interventions
- DEVICE Verofilcon A toric soft contact lenses
- DEVICE Verofilcon A spherical soft contact lenses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-08-30 |
| Est. Completion | 2025-03-11 |
Why NCT06462456 stopped before completion
NCT06462456 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Verofilcon A toric soft contact lenses is the first listed.
NCT06462456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06462456 about?
NCT06462456 is a clinical study titled "Post-market Clinical Follow-up Study of Alcon PRECISION1™ Spherical and PRECISION1™ for Astigmatism Soft Contact Lenses". The purpose of this study is to assess long term performance and safety of verofilcon A soft contact lenses in a real-world setting in a population of 7 years or older having at least 1 year of verofilcon A (sphere or toric) contact lens wear in a daily wear and daily disposable modality.
What is the current status of trial NCT06462456?
This trial is currently terminated. The enrollment target is 140 participants. The study started on 2024-08-30. Estimated completion is 2025-03-11.
What interventions are being tested in trial NCT06462456?
The interventions under investigation include: Verofilcon A toric soft contact lenses (DEVICE), Verofilcon A spherical soft contact lenses (DEVICE).
Who is sponsoring clinical trial NCT06462456?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI